Acadia Pharmaceuticals Launches Daybue Stix for Rett Syndrome Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 07 2026
0mins
Should l Buy ACAD?
Acadia Pharmaceuticals announced Daybue Stix is now broadly available in the United States for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. The new formulation, approved by the U.S. Food and Drug Administration, FDA, in December 2025, is bioequivalent to the original DAYBUE oral solution, delivering the same efficacy and safety profile, while offering children and adults living with Rett syndrome new flexibility and choice regarding the dose volume and taste of their DAYBUE treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACAD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACAD
Wall Street analysts forecast ACAD stock price to rise
12 Analyst Rating
7 Buy
5 Hold
0 Sell
Moderate Buy
Current: 22.090
Low
23.00
Averages
31.17
High
40.00
Current: 22.090
Low
23.00
Averages
31.17
High
40.00
About ACAD
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. It develops and commercializes medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and ACP-711. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its early-stage research programs and product candidates include ACP-211, ACP-2591, ACP-271, and Antisense Oligonucleotide (ASO) Programs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Acadia Pharmaceuticals to Present Multiple Data at AAN Annual Meeting
- Data Presentation: Acadia Pharmaceuticals will present multiple original data sets at the 2026 American Academy of Neurology Annual Meeting, reflecting the company's ongoing commitment to research in neurological diseases.
- LOTUS Study Findings: The company will share real-world data on DAYBUE® (trofinetide) in adults with Rett syndrome, highlighting its benefits and tolerability in clinical practice, which may enhance market acceptance of the drug.
- Parkinson's Disease Psychosis Analysis: Acadia will also present exploratory analyses of NUPLAZID® (pimavanserin) treatment response trajectories in Parkinson's disease psychosis patients, revealing the impact of baseline sleep disturbances on treatment outcomes, potentially informing personalized treatment approaches.
- ACP-711 Development Progress: The company will debut translational research and pharmacokinetic data for ACP-711, supporting its development for essential tremor, showcasing Acadia's forward-looking strategy in neurological drug development.
See More
Acadia Launches DAYBUE STIX Powder for Rett Syndrome Treatment
- New Drug Launch: Acadia Pharmaceuticals announced that DAYBUE STIX (trofinetide) powder formulation is now broadly available in the U.S. for treating Rett syndrome in patients aged two and older, marking a significant innovation in the neurological disease sector.
- High Patient Satisfaction: Initial feedback indicates that over 80% of early users reported satisfaction with DAYBUE STIX, highlighting its advantages in flexibility and portability, which may enhance the medication experience for patients.
- Expert Consensus Support: A steering group of experts from the International Rett Syndrome Foundation has recognized trofinetide oral solution as part of the standard of care, emphasizing the importance of individualized decision-making to optimize treatment outcomes for patients and families, further solidifying DAYBUE STIX's clinical position.
- Diverse Administration Options: DAYBUE STIX can be mixed with various water-based liquids, providing personalized taste options that cater to the unique needs of patients and caregivers, aligning with modern healthcare's patient-centered treatment philosophy.
See More
BofA Upgrades Acadia Pharmaceuticals to Buy Amid Price Pullback
- Rating Upgrade: BofA Securities has upgraded Acadia Pharmaceuticals (ACAD) from neutral to buy, citing that the company's fundamentals remain intact despite a 25% pullback in share price since the beginning of the year, which is attributed mainly to macro factors.
- Price Target Maintained: The bank maintains a price target of $29 for Acadia, which implies approximately 38% upside based on the March 24 close, reflecting confidence in the company's future performance.
- Sales Forecast: Analysts project that steady sales of Nuplazid (pimavanserin) will help mitigate further downside risks, estimating peak sales of $888 million by 2029, indicating strong market potential for the product.
- Pipeline Opportunity: While the company estimates its pipeline could offer an $11 billion opportunity, BofA believes this figure is currently discounted and may provide upside, reiterating a 40% likelihood of success for remlifanserin with projected peak sales of $2.1 billion in 2038.
See More
Latest Rating Changes on Wall Street
- Tesla Neutral Rating: Goldman Sachs maintains a neutral stance on Tesla, expressing caution regarding its semiconductor ventures, noting a mixed track record in semiconductor engineering, while suggesting potential applications for inference chips in data centers and distributed computing remain to be seen.
- Upgrade Based on Iran War: Wells Fargo upgrades Kinetik, ONEOK, and Enterprise Products Partners from equal weight to overweight, anticipating that the Iran war will create a structural shift in global energy markets, boosting demand for U.S. energy, particularly in Permian gas and NGL supply.
- ESCO Technologies Buy Initiation: Deutsche Bank initiates coverage on ESCO Technologies with a Buy rating and a $350 target price, highlighting its potential for “defensive growth at a discount” in the aerospace and defense sectors, indicating strong confidence in the company's future.
- Arm Rating Upgrade: Wolfe upgrades Arm from market perform to outperform, citing the company's recent in-house chip launch and significantly increased earnings forecasts for FY28 and FY31, setting a target price of $166, reflecting optimism about its new business model.
See More
Neuren and Acadia Request Re-examination for Rett Syndrome Drug
- Re-examination Request: Acadia Pharmaceuticals will request a re-examination of the CHMP's opinion on trofinetide, aimed at treating Rett syndrome in patients aged two and older, reflecting ongoing commitment to drug approval efforts.
- Market Authorization: Trofinetide is already approved in the U.S., Canada, and Israel, representing the first and only treatment for Rett syndrome, highlighting its potential and significance in the global market.
- Executive Commentary: Acadia CEO Catherine Owen Adams expressed disappointment over the CHMP's refusal but remains optimistic about the drug's meaningful benefits for Rett syndrome patients, emphasizing positive feedback from patients and clinicians.
- Market Reaction: ACAD shares fell 7.13% to $22.81 during regular trading on Monday, yet gained 0.04% in after-hours trading, indicating cautious optimism in the market regarding the drug's future potential.
See More
Aardvark Pauses PWS Trial, Shares Plunge 53%
- Trial Pause Reason: Aardvark Therapeutics announced a voluntary pause of its ARD-101 trial for Prader-Willi Syndrome due to cardiac observations in a healthy volunteer study, with data release now expected to be delayed until Q3 2026, potentially impacting the company's future R&D trajectory.
- Severe Market Reaction: Following the trial pause announcement, Aardvark's shares plunged 53% in after-hours trading, reflecting extreme investor concern over the company's outlook, which may lead to financing challenges and diminished market confidence.
- Competitor Dynamics: In contrast, Soleno Therapeutics' VYKAT XR has become the first FDA-approved treatment for hyperphagia in Prader-Willi Syndrome, despite facing short-selling pressure and safety concerns from Scorpion Capital, highlighting the intense competition in the market.
- Industry-Wide Challenges: Against the backdrop of Aardvark's trial pause, Acadia Pharmaceuticals also halted development of its intranasal Carbetocin, indicating that the challenges and risks associated with successful R&D in the Prader-Willi Syndrome treatment space are increasing, which could affect the overall investment attractiveness of the sector.
See More
Acadia Pharmaceuticals to Present Multiple Data at AAN Annual Meeting
- Data Presentation: Acadia Pharmaceuticals will present multiple original data sets at the 2026 American Academy of Neurology Annual Meeting, reflecting the company's ongoing commitment to research in neurological diseases.
- LOTUS Study Findings: The company will share real-world data on DAYBUE® (trofinetide) in adults with Rett syndrome, highlighting its benefits and tolerability in clinical practice, which may enhance market acceptance of the drug.
- Parkinson's Disease Psychosis Analysis: Acadia will also present exploratory analyses of NUPLAZID® (pimavanserin) treatment response trajectories in Parkinson's disease psychosis patients, revealing the impact of baseline sleep disturbances on treatment outcomes, potentially informing personalized treatment approaches.
- ACP-711 Development Progress: The company will debut translational research and pharmacokinetic data for ACP-711, supporting its development for essential tremor, showcasing Acadia's forward-looking strategy in neurological drug development.
See More
Acadia Launches DAYBUE STIX Powder for Rett Syndrome Treatment
- New Drug Launch: Acadia Pharmaceuticals announced that DAYBUE STIX (trofinetide) powder formulation is now broadly available in the U.S. for treating Rett syndrome in patients aged two and older, marking a significant innovation in the neurological disease sector.
- High Patient Satisfaction: Initial feedback indicates that over 80% of early users reported satisfaction with DAYBUE STIX, highlighting its advantages in flexibility and portability, which may enhance the medication experience for patients.
- Expert Consensus Support: A steering group of experts from the International Rett Syndrome Foundation has recognized trofinetide oral solution as part of the standard of care, emphasizing the importance of individualized decision-making to optimize treatment outcomes for patients and families, further solidifying DAYBUE STIX's clinical position.
- Diverse Administration Options: DAYBUE STIX can be mixed with various water-based liquids, providing personalized taste options that cater to the unique needs of patients and caregivers, aligning with modern healthcare's patient-centered treatment philosophy.
See More
BofA Upgrades Acadia Pharmaceuticals to Buy Amid Price Pullback
- Rating Upgrade: BofA Securities has upgraded Acadia Pharmaceuticals (ACAD) from neutral to buy, citing that the company's fundamentals remain intact despite a 25% pullback in share price since the beginning of the year, which is attributed mainly to macro factors.
- Price Target Maintained: The bank maintains a price target of $29 for Acadia, which implies approximately 38% upside based on the March 24 close, reflecting confidence in the company's future performance.
- Sales Forecast: Analysts project that steady sales of Nuplazid (pimavanserin) will help mitigate further downside risks, estimating peak sales of $888 million by 2029, indicating strong market potential for the product.
- Pipeline Opportunity: While the company estimates its pipeline could offer an $11 billion opportunity, BofA believes this figure is currently discounted and may provide upside, reiterating a 40% likelihood of success for remlifanserin with projected peak sales of $2.1 billion in 2038.
See More
Latest Rating Changes on Wall Street
- Tesla Neutral Rating: Goldman Sachs maintains a neutral stance on Tesla, expressing caution regarding its semiconductor ventures, noting a mixed track record in semiconductor engineering, while suggesting potential applications for inference chips in data centers and distributed computing remain to be seen.
- Upgrade Based on Iran War: Wells Fargo upgrades Kinetik, ONEOK, and Enterprise Products Partners from equal weight to overweight, anticipating that the Iran war will create a structural shift in global energy markets, boosting demand for U.S. energy, particularly in Permian gas and NGL supply.
- ESCO Technologies Buy Initiation: Deutsche Bank initiates coverage on ESCO Technologies with a Buy rating and a $350 target price, highlighting its potential for “defensive growth at a discount” in the aerospace and defense sectors, indicating strong confidence in the company's future.
- Arm Rating Upgrade: Wolfe upgrades Arm from market perform to outperform, citing the company's recent in-house chip launch and significantly increased earnings forecasts for FY28 and FY31, setting a target price of $166, reflecting optimism about its new business model.
See More
Neuren and Acadia Request Re-examination for Rett Syndrome Drug
- Re-examination Request: Acadia Pharmaceuticals will request a re-examination of the CHMP's opinion on trofinetide, aimed at treating Rett syndrome in patients aged two and older, reflecting ongoing commitment to drug approval efforts.
- Market Authorization: Trofinetide is already approved in the U.S., Canada, and Israel, representing the first and only treatment for Rett syndrome, highlighting its potential and significance in the global market.
- Executive Commentary: Acadia CEO Catherine Owen Adams expressed disappointment over the CHMP's refusal but remains optimistic about the drug's meaningful benefits for Rett syndrome patients, emphasizing positive feedback from patients and clinicians.
- Market Reaction: ACAD shares fell 7.13% to $22.81 during regular trading on Monday, yet gained 0.04% in after-hours trading, indicating cautious optimism in the market regarding the drug's future potential.
See More
Aardvark Pauses PWS Trial, Shares Plunge 53%
- Trial Pause Reason: Aardvark Therapeutics announced a voluntary pause of its ARD-101 trial for Prader-Willi Syndrome due to cardiac observations in a healthy volunteer study, with data release now expected to be delayed until Q3 2026, potentially impacting the company's future R&D trajectory.
- Severe Market Reaction: Following the trial pause announcement, Aardvark's shares plunged 53% in after-hours trading, reflecting extreme investor concern over the company's outlook, which may lead to financing challenges and diminished market confidence.
- Competitor Dynamics: In contrast, Soleno Therapeutics' VYKAT XR has become the first FDA-approved treatment for hyperphagia in Prader-Willi Syndrome, despite facing short-selling pressure and safety concerns from Scorpion Capital, highlighting the intense competition in the market.
- Industry-Wide Challenges: Against the backdrop of Aardvark's trial pause, Acadia Pharmaceuticals also halted development of its intranasal Carbetocin, indicating that the challenges and risks associated with successful R&D in the Prader-Willi Syndrome treatment space are increasing, which could affect the overall investment attractiveness of the sector.
See More
